Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-22T08:01:16.586Z Has data issue: false hasContentIssue false
  • English
  • Français

The Appropriate Role of Computerized Postmarketing Surveillance

Published online by Cambridge University Press:  07 November 2014

Brian L. Strom
Brian L. Strom*
Affiliation:
Dr. Strom is chair of the Department of Biostatistics and Epidemiology, director of the Center for Clinical Epidemiology and Biostatistics
Get access Rights & Permissions [Opens in a new window]

Abstract

Pharmacoepidemiology, the study of the effects of drugs in large numbers of people, is a relatively new discipline that applies the methods of epidemiology to clinical pharmacology. Premarketing clinical trials remain the only way to scientifically determine whether a drug is causally effective, yet these trials do not provide information that allows for estimates about rare, late, or off-label toxicities associated with the drug in question. Increasing concern about common and debilitating adverse effects of medications has highlighted the need for enhanced postmarketing surveillance to follow up on clinical trials. There is a further concern regarding the broader issue of the risk-benefit ratio of certain medications. Computerized databases are a good source of information on which to lay the foundations of postmarketing research. A system of cross-linked computerized medical records may better enable researchers and physicians to realistically monitor postmarketing safety and incorporate monitoring benefits. The same research could also elucidate the net public health effect of regulatory decisions. The Veterans Affairs database in the United States and PHARMO in the Netherlands may represent good models on which to base future postmarketing surveillance studies.

In this expert roundtable supplement, Brian L. Strom, MD, provides an overview of the appropriate use of large computer databases in pharmacoepidemiology studies. Philip Wang, MD, DrPH, discusses the advantages of pharmacoepidemiologic studies over clinical trials in correctly detecting drug safety issues. Francesca Cunningham, PharmD, reviews a large computer database that is currently in use within the VA healthcare system, and Ron M.C. Herings, PharmD, PhD, discusses the development of the PHARMO system in the Netherlands.

This summary is based heavily on the concepts presented in: Strom BL. What is pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Sussex: John Wiley; 2005:3–15; and Strom BL. Overview of study designs available for pharmacoepidemiology studies. In: Strom BL, ed. Pharmacoepidemiology. 4th ed. Sussex: John Wiley, 2005:17–28.

Type
Research Article
Information
CNS Spectrums , Volume 12 , Issue S16 , 2007 , pp. 3 - 7
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Strom, BL, ed. Pharmacoepidemiology. 4th ed. Sussex: John Wiley, 2005.Google Scholar
2.Lasser, KE, Allen, PD, Woolhandler, SJ, Himmelstein, DU, Wolfe, SM, Bor, DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215–2220.Google Scholar
3.Bakke, OM, Manocchia, M, de Abajo, F, Kaitin, KI, Lasagna, L. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: a regulatory perspective. Clin Pharmacol Ther. 1995;58:108–117.CrossRefGoogle ScholarPubMed
4. US General Accounting Office. FDA Drug Review: Postapproval Risks 1976–85. GAO/PEMD–90–15, April 1990:24.Google Scholar
5.Strom, BL. Overview of automated databases in pharmacoepidemiology. Chapter 13 In: Strom, BL, ed. Pharmacoepidemiology. 4th ed. Sussex: John Wiley, 2005:219–222.Google Scholar
6.Hennessy, S, Carson, JL, Ray, WA, Strom, BL. Medicaid databases. Chapter 18 In: Strom, BL, ed. Pharmacoepidemiology. 4th ed. Sussex: John Wiley, 2005:281–294.Google Scholar